Short Bowel Syndrome (SBS) Market is estimated to increase at a growth rate of 19.6% CAGR over the forecast period from 2024 to 2030.
The global Short Bowel Syndrome (SBS) Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug Class (GLP-2, Growth Hormone, Glutamine, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others).
An Introduction to Short Bowel Syndrome (SBS) Market in 2024
The Short Bowel Syndrome (SBS) Market comprises pharmaceuticals, nutritional therapies, and surgical interventions used in the management of short bowel syndrome, a condition characterized by reduced intestinal length or function due to surgical resection, congenital defects, or gastrointestinal diseases. Treatment modalities include parenteral nutrition, enteral feeding, growth factors, gut hormones, and intestinal rehabilitation programs aimed at improving nutrient absorption, intestinal adaptation, and quality of life for patients with SBS. Market dynamics focus on novel therapies, bowel transplantation, microbiome research, and patient-centered approaches to optimize intestinal health and nutritional support in SBS management.
Short Bowel Syndrome (SBS) Market Competitive Landscape
The global Short Bowel Syndrome (SBS) Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Short Bowel Syndrome (SBS) Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Short Bowel Syndrome (SBS) Industry include- 9 Meters Biopharma, Ardelyx, Hanmi Pharm.Co. Ltd, Merck KGaA, Nestle Health Science, Nutrinia, OPKO Health Inc, OxThera Inc, Sancilio&Company Inc, Takeda Pharmaceutical Company Ltd, VectivBio AG, Zealand Pharma.
Short Bowel Syndrome Market Trend: Advancements in Minimally Invasive Procedures
A prominent trend in the Short Bowel Syndrome market is the increasing adoption of minimally invasive surgical procedures for the management of the condition. With technological advancements and surgical innovations, there's a shift towards less invasive approaches such as laparoscopic bowel lengthening procedures, endoscopic interventions, and intestinal transplantation techniques. This trend aims to minimize surgical trauma, reduce postoperative complications, and improve patient outcomes, driving the demand for minimally invasive treatment options in the management of Short Bowel Syndrome.
Short Bowel Syndrome Market Driver: Rising Prevalence of Intestinal Failure
The primary driver for the Short Bowel Syndrome market is the rising prevalence of intestinal failure and associated conditions contributing to Short Bowel Syndrome. Factors such as intestinal resections due to trauma, ischemia, Crohn's disease, and other gastrointestinal disorders result in insufficient bowel length, malabsorption, and dependence on parenteral nutrition. As the incidence of intestinal failure increases, there's a growing demand for effective treatments that address the underlying causes, optimize intestinal function, and reduce dependence on parenteral support, highlighting the need for innovative therapeutic interventions in the Short Bowel Syndrome market.
Short Bowel Syndrome Market Opportunity: Development of Intestinal Rehabilitation Therapies
An opportunity exists in the development of intestinal rehabilitation therapies tailored to the specific needs of individuals with Short Bowel Syndrome. Intestinal rehabilitation programs encompass nutritional support, pharmacological interventions, bowel adaptation strategies, and multidisciplinary care to promote bowel adaptation, enhance nutrient absorption, and improve quality of life for patients with intestinal failure. By investing in research and clinical trials focused on intestinal rehabilitation approaches, pharmaceutical companies and healthcare providers can address the unmet needs of individuals with Short Bowel Syndrome, optimize patient outcomes, and advance the standard of care in the management of the condition.
Short Bowel Syndrome Market Share Analysis: GLP-2 Therapy for Short Bowel Syndrome is the fastest growing market segment over the forecast period to 2030
In the realm of Short Bowel Syndrome (SBS) treatment, GLP-2 (Glucagon-like Peptide-2) therapy emerges as the fastest-growing segment. GLP-2 is a naturally occurring peptide hormone known for its role in promoting intestinal growth and function. Patients with SBS often experience malabsorption and nutrient deficiencies due to reduced intestinal surface area, leading to significant morbidity and mortality. GLP-2 therapy works by stimulating intestinal epithelial cell proliferation, enhancing nutrient absorption, and reducing dependence on parenteral nutrition. Recent clinical trials have demonstrated the efficacy of GLP-2 analogs in improving intestinal adaptation, reducing diarrhea, and enhancing quality of life in SBS patients. As a result, there has been a surge in demand for GLP-2 therapy, with increasing adoption in clinical practice. The availability of GLP-2 analogs through hospital and retail pharmacies has facilitated broader patient access, further driving market growth. With ongoing research and development efforts focused on optimizing dosing regimens and improving patient outcomes, the market for GLP-2 therapy for SBS is poised for continued expansion in the coming years.
Short Bowel Syndrome (SBS) Market Segmentation
By Drug Class
GLP-2
Growth Hormone
Glutamine
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Short Bowel Syndrome (SBS) Companies
9 Meters Biopharma
Ardelyx
Hanmi Pharm.Co. Ltd
Merck KGaA
Nestle Health Science
Nutrinia
OPKO Health Inc
OxThera Inc
Sancilio&Company Inc
Takeda Pharmaceutical Company Ltd
VectivBio AG
Zealand Pharma
* List not Exhaustive
Reasons to Buy the Short Bowel Syndrome (SBS) Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Short Bowel Syndrome (SBS) Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Short Bowel Syndrome (SBS) Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Short Bowel Syndrome (SBS) Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Short Bowel Syndrome (SBS) Market Size Outlook, $ Million, 2021 to 2030
3.2 Short Bowel Syndrome (SBS) Market Outlook by Type, $ Million, 2021 to 2030
3.3 Short Bowel Syndrome (SBS) Market Outlook by Product, $ Million, 2021 to 2030
3.4 Short Bowel Syndrome (SBS) Market Outlook by Application, $ Million, 2021 to 2030
3.5 Short Bowel Syndrome (SBS) Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Short Bowel Syndrome (SBS) Industry
4.2 Key Market Trends in Short Bowel Syndrome (SBS) Industry
4.3 Potential Opportunities in Short Bowel Syndrome (SBS) Industry
4.4 Key Challenges in Short Bowel Syndrome (SBS) Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Short Bowel Syndrome (SBS) Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Short Bowel Syndrome (SBS) Market Outlook by Segments
7.1 Short Bowel Syndrome (SBS) Market Outlook by Segments, $ Million, 2021- 2030
By Drug Class
GLP-2
Growth Hormone
Glutamine
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
8 North America Short Bowel Syndrome (SBS) Market Analysis and Outlook To 2030
8.1 Introduction to North America Short Bowel Syndrome (SBS) Markets in 2024
8.2 North America Short Bowel Syndrome (SBS) Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Short Bowel Syndrome (SBS) Market size Outlook by Segments, 2021-2030
By Drug Class
GLP-2
Growth Hormone
Glutamine
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
9 Europe Short Bowel Syndrome (SBS) Market Analysis and Outlook To 2030
9.1 Introduction to Europe Short Bowel Syndrome (SBS) Markets in 2024
9.2 Europe Short Bowel Syndrome (SBS) Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Short Bowel Syndrome (SBS) Market Size Outlook by Segments, 2021-2030
By Drug Class
GLP-2
Growth Hormone
Glutamine
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
10 Asia Pacific Short Bowel Syndrome (SBS) Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Short Bowel Syndrome (SBS) Markets in 2024
10.2 Asia Pacific Short Bowel Syndrome (SBS) Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Short Bowel Syndrome (SBS) Market size Outlook by Segments, 2021-2030
By Drug Class
GLP-2
Growth Hormone
Glutamine
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
11 South America Short Bowel Syndrome (SBS) Market Analysis and Outlook To 2030
11.1 Introduction to South America Short Bowel Syndrome (SBS) Markets in 2024
11.2 South America Short Bowel Syndrome (SBS) Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Short Bowel Syndrome (SBS) Market size Outlook by Segments, 2021-2030
By Drug Class
GLP-2
Growth Hormone
Glutamine
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
12 Middle East and Africa Short Bowel Syndrome (SBS) Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Short Bowel Syndrome (SBS) Markets in 2024
12.2 Middle East and Africa Short Bowel Syndrome (SBS) Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Short Bowel Syndrome (SBS) Market size Outlook by Segments, 2021-2030
By Drug Class
GLP-2
Growth Hormone
Glutamine
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
9 Meters Biopharma
Ardelyx
Hanmi Pharm.Co. Ltd
Merck KGaA
Nestle Health Science
Nutrinia
OPKO Health Inc
OxThera Inc
Sancilio&Company Inc
Takeda Pharmaceutical Company Ltd
VectivBio AG
Zealand Pharma
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
